Radiology still refuses to use GAD Meta-analysis:16 studies (n=4931) ✳️NSF 0/4931 (0%; UL 95%CI, 0.07%). 🚫Gadobenate dimeglumine (0/3167; UL,0.12%) 🚫Gadoterate meglumine (0/1204; UL,0.31%) 🚫Gadobutrol (0/330; UL,1.11%) 🚫Gadoteridol (0/230; UL,1.59%)| htt
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
Good news! Very low risk
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
RT @JWeirMcCall: 💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0…
💥Such an important paper! 🎯Risk of NSF pretty much the same as risk of anaphylaxis in CKD 4/5 (eg. Very very low, as in 0.07% low) https://t.co/tOFUB1meyn
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
@cwrightmd @DocAroundThClok @DShadowgazer I’m just gonna leave this right here... https://t.co/G92HLzToKG
New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gadolinium-Based Contrast Agent: Systematic Review & Meta-analysis https://t.co/4XDcLeCvNE
RT @IanPaddick1: If anyone has been forced to plan an #SRS treatment with a no-contrast MR scan because a radiologist insists that the pati…
RT @frederickruberg: Coincident to #SCMR2020. Further evidence that risk of NSF is virtually nonexistent even in CKD4-5 or ESRD when using…
Systematic review & meta-analysis by @umichradiology on the risk of NSF in patients w stage 4 or 5 chronic kidney disease exposed to a group II GBCA. https://t.co/Tzx4hFDxaA
The next time radiology calls me to refuse GAD for an MRI that I ordered, can I just show them these results 🤔
RT @frederickruberg: Coincident to #SCMR2020. Further evidence that risk of NSF is virtually nonexistent even in CKD4-5 or ESRD when using…
Linking this recent paper https://t.co/eTS8pWQPm3
RT @frederickruberg: Coincident to #SCMR2020. Further evidence that risk of NSF is virtually nonexistent even in CKD4-5 or ESRD when using…
RT @frederickruberg: Coincident to #SCMR2020. Further evidence that risk of NSF is virtually nonexistent even in CKD4-5 or ESRD when using…
Coincident to #SCMR2020. Further evidence that risk of NSF is virtually nonexistent even in CKD4-5 or ESRD when using group II GBCA's. Harms of withholding contrast in this setting may exceed risk. https://t.co/jagsTiM1ge
RT @francisdeng: A meta-analysis of 16 studies with 4931 administrations of group II gadolinium-based contrast agents found the risk of nep…
Love me some gad!
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @tripdatabase: New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gad…
New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gadolinium-Based Contrast Agent: Systematic Review & Meta-analysis https://t.co/YgHy20Yf0R
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @Luca_Arcari88: The risk of nephrogenic systemic fibrosis after gadolinium contrast agent administration in patients with chronic kidney…
The risk of nephrogenic systemic fibrosis after gadolinium contrast agent administration in patients with chronic kidney disease: much ado about nothing? https://t.co/2dhvqWHIJn The risk of not performing the examination potentially exceeds the very low r
@Neuro_Matt @DanOfChorlton @jamiekwillows @DrBenLovell Interestingly https://t.co/mhTOfW0GJg seems to contradicts even NSF being a thing.
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @nuromri: Risk of NSF in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: metaanalysis of 16 studie…
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @vallesamuel2: Potential harms of withholding Gad may outweigh the risk of NSF in patients with Stage 4 and 5 CKD.
Potential harms of withholding Gad may outweigh the risk of NSF in patients with Stage 4 and 5 CKD.
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @nuromri: Risk of NSF in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: metaanalysis of 16 studie…
RT @HeartOTXHeartMD: “Risk of #NSF ( Nephrogenic Systemic Fibrosis ) from group II GBCA administration in stage 4&5 #CKD is likely < 0.07%.…
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @nuromri: Risk of NSF in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: metaanalysis of 16 studie…
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
Not everyone has to give expert opinion. We see this often in #pretransplant #kidney patients. Data is there. https://t.co/97n69pLPkD
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
RT @AlexandreLoupy: 🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANe…
🌟Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease 👉Is Zero Good Enough? Nice @JAMAInternalMed @JAMANetwork meta analysis https://t.co/y02KEqtVQK https://t.co/D3H1YIrhOx
RT @tripdatabase: New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gad…
New2Trip: Risk of Nephrogenic Systemic Fibrosis in Patients w/ Stage 4 or 5 Chronic Kidney Disease Receiving Group II Gadolinium-Based Contrast Agent: Systematic Review & Meta-analysis https://t.co/YgHy20Yf0R
RT @kidney_boy: worst hitting slump ever... “The incidence of NSF in patients with stage 4 or 5 CKD across all 16 studies was 0 of 4931.”…
RT @HeartOTXHeartMD: “Risk of #NSF ( Nephrogenic Systemic Fibrosis ) from group II GBCA administration in stage 4&5 #CKD is likely < 0.07%.…
Risk of NSF in Patients With Stage 4 or 5 CKD Receiving a Group II Gadolinium-Based Contrast Agent: metaanalysis of 16 studies and 4931 patients, incidence of NSF after administration of a group II GBCA in patients with stage 4 or 5 CKD was 0% https://t.c
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
@tobiasgilk @Wagner_Nephro @SamiAlasfar @Renaltubules Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt https://t.co/9UkNecR85v
RT @drlng23: Benefit outweighs the risk of NSF in CKD stage 4 and 5.
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
Benefit outweighs the risk of NSF in CKD stage 4 and 5.
@jamiekwillows It was @KidneyCathy tweeting this that made me wonder #NephJC https://t.co/6QIO9YqihU
We are discussing this paper from @JAMAInternalMed on the risk of NSF after class II GBCA https://t.co/9XaxK56MC6 #nephjc
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
We are discussing this paper from @JAMAInternalMed on the risk of NSF after class II GBCA https://t.co/9XaxK5oo0G #NephJC
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
NSF in #CKD After Gadolinium-Based Contrast Agent Receipt https://t.co/ihhnYte6P8 today #nephjc #ckd #radiology #renal @ISNeducation @ASNKidney @ERAEDTA
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
RT @NephJC: We are discussing this paper from @JAMAInternalMed on the risk of NSF after class II GBCA https://t.co/9XaxK5oo0G #NephJC
RT @edgarvlermamd: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolini…
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis ca. 2019 #VisualAbstract by @VickiSandys1 #NephJC #Nephpearls 👉🏼 https
We are discussing this paper from @JAMAInternalMed on the risk of NSF after class II GBCA https://t.co/9XaxK5oo0G #NephJC
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…
RT @SVNefro: El riesgo de Fibrosis nefrogÉnica sistemica con Gadolinio (clase II) parece ser infima. ¿Nos estamos preocupando demasiado?Gre…